BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol 2015;29:19-34. [PMID: 25585348 DOI: 10.1155/2015/692408] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Liu HY, Cheung CYS, Cooper SE. Ribavirin-induced anaemia reduced tacrolimus level in a hepatitis C patient receiving haemodialysis. BMJ Case Rep 2018;2018:bcr-2017-222477. [PMID: 29669765 DOI: 10.1136/bcr-2017-222477] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Quintela BM, Conway JM, Hyman JM, Reis RF, dos Santos RW, Lobosco M, Perelson AS. An Age-based Multiscale Mathematical Model of the Hepatitis C Virus Life-cycle During Infection and Therapy: Including Translation and Replication. In: Torres I, Bustamante J, Sierra DA, editors. VII Latin American Congress on Biomedical Engineering CLAIB 2016, Bucaramanga, Santander, Colombia, October 26th -28th, 2016. Singapore: Springer; 2017. pp. 508-11. [DOI: 10.1007/978-981-10-4086-3_128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
3 Castro R, Perazzo H, Grinsztejn B, Veloso VG, Hyde C. Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. Int J Hepatol. 2015;2015:852968. [PMID: 26693356 DOI: 10.1155/2015/852968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
4 Cousien A, Leclerc P, Morissette C, Bruneau J, Roy É, Tran VC, Yazdanpanah Y, Cox J. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study. BMC Infect Dis 2017;17:162. [PMID: 28222681 DOI: 10.1186/s12879-017-2256-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
5 Grzegorzewska AE. Genetic Polymorphisms within Interferon-λ Region and Interferon-λ3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses. CMC 2019;26:4832-51. [DOI: 10.2174/0929867325666180719121142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Chamorro-de-vega E, Gimenez-manzorro A, Rodriguez-gonzalez CG, Escudero-vilaplana V, Collado Borrell R, Ibañez-garcia S, Lallana Sainz E, Lobato Matilla E, Lorenzo-pinto A, Manrique-rodriguez S, Fernandez-llamazares CM, Marzal-alfaro M, Ribed A, Romero Jimenez RM, Sarobe Gonzalez C, Herranz A, Sanjurjo M. Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice. Ann Pharmacother 2016;50:901-8. [DOI: 10.1177/1060028016659306] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
7 Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Reference Citation Analysis]
8 Luhnen M, Waffenschmidt S, Gerber-Grote A, Hanke G. Health Economic Evaluations of Sofosbuvir for Treatment of Chronic Hepatitis C: a Systematic Review. Appl Health Econ Health Policy. 2016;14:527-543. [PMID: 27329481 DOI: 10.1007/s40258-016-0253-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
9 Marotta P, Bailey R, Elkashab M, Farley J, Feinman SV, Peltekian K, Poliquin M, Witt-Sullivan H, Rampakakis E, Drolet M, Cooper C. Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies. Eur J Clin Microbiol Infect Dis 2016;35:597-609. [PMID: 26851949 DOI: 10.1007/s10096-016-2576-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Pathania S, Rawal RK, Singh PK. RdRp (RNA-dependent RNA polymerase): A key target providing anti-virals for the management of various viral diseases. J Mol Struct 2022;1250:131756. [PMID: 34690363 DOI: 10.1016/j.molstruc.2021.131756] [Reference Citation Analysis]
11 Puri P, Anand AC, Saraswat VA, Acharya SK, Dhiman RK, Sarin SK, Singh SP, Chawla YK, Aggarwal R, Amarapurkar D, Arora A, Dixit VK, Sood A, Shah S, Duseja A, Kapoor D, Shalimar, Madan K, Pande G, Nagral A, Kar P, Koshy A, Puri AS, Eapen CE, Thareja S. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015. J Clin Exp Hepatol 2015;5:221-38. [PMID: 26628840 DOI: 10.1016/j.jceh.2015.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
12 O'Keefe-Markman C, Lea KD, McCabe C, Hyshka E, Bubela T. Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment. BMC Public Health 2020;20:89. [PMID: 31959155 DOI: 10.1186/s12889-020-8190-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Kiang TKL. Clinical Pharmacokinetics and Drug-Drug Interactions of Elbasvir/Grazoprevir. Eur J Drug Metab Pharmacokinet 2018;43:509-31. [PMID: 29557529 DOI: 10.1007/s13318-018-0471-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
14 Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, Gallagher L, Klein MB, Krajden M, Shoukry NH, Taylor LE, Grebely J; Canadian Network on Hepatitis C (CanHepC). Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open 2016;4:E605-14. [PMID: 28018873 DOI: 10.9778/cmajo.20160008] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 9.2] [Reference Citation Analysis]
15 Pecoraro V, Cariani E, Villa E, Trenti T. Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review. Eur J Clin Invest 2016;46:737-48. [PMID: 27376688 DOI: 10.1111/eci.12656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
16 Socías ME, Ti L, Dong H, Shoveller J, Kerr T, Montaner J, Milloy MJ. High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs. HIV Med 2017;18:647-54. [PMID: 28294492 DOI: 10.1111/hiv.12501] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
17 Francheville JW, Rankin R, Beck J, Hoare C, Materniak S, German G, Barrett L, Bunimov-Wall N, Smyth D. Early Successes in an Open Access, Provincially Funded Hepatitis C Treatment Program in Prince Edward Island. Ann Hepatol 2017;16:749-58. [PMID: 28809740 DOI: 10.5604/01.3001.0010.2757] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
18 Conway B, Smyth D, Thomas R, Wong A, Sebastiani G, Cooper C, Shah H, Kumar R, Deutsch G, Watson T. Characterizing risk behaviour and reinfection rates for successful programs to engage core transmitters in HCV elimination (C-RESPECT). CanLivJ 2021;4:346-59. [DOI: 10.3138/canlivj-2021-0005] [Reference Citation Analysis]
19 Cervo A, Shengir M, Patel K, Sebastiani G. NASH in HIV. Curr HIV/AIDS Rep 2020;17:601-14. [PMID: 32984925 DOI: 10.1007/s11904-020-00531-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Jung YK. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3]. Korean J Gastroenterol 2016;67:132-6. [PMID: 26996182 DOI: 10.4166/kjg.2016.67.3.132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
21 Enache EL, Sin A, Enache LS, Bancu L. Triplex High-Resolution Melting Assay for the Simultaneous Assessment of IFNL3 rs12979860, ABCB11 rs2287622, and RNF7 rs16851720 Genotypes in Chronic Hepatitis C Patients. J Mol Diagn 2017;19:857-69. [PMID: 28860020 DOI: 10.1016/j.jmoldx.2017.07.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
22 Fang C, Mei J, Tian H, Liou YL, Rong D, Zhang W, Liao Q, Wu N. CSF3 Is a Potential Drug Target for the Treatment of COVID-19. Front Physiol 2020;11:605792. [PMID: 33551833 DOI: 10.3389/fphys.2020.605792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ng E, Myers RP, Manuel D, Sanmartin C. Hospital stays for hepatitis B or C virus infection or primary liver cancer among immigrants: a census-linked population-based cohort study. CMAJ Open. 2016;4:E162-E168. [PMID: 27398359 DOI: 10.9778/cmajo.20150117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
24 Young S, Wood E, Milloy MJ, DeBeck K, Dobrer S, Nosova E, Kerr T, Hayashi PhD K. Hepatitis C cascade of care among people who inject drugs in Vancouver, Canada. Subst Abus 2018;39:461-8. [PMID: 29949450 DOI: 10.1080/08897077.2018.1485128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
25 Khan B, Singer LG, Lilly LB, Chaparro C, Martinu T, Juvet S, Pipkin M, Waddell TK, Keshavjee S, Humar A, Cypel M. Successful Lung Transplantation From Hepatitis C Positive Donor to Seronegative Recipient. Am J Transplant 2017;17:1129-31. [PMID: 27873483 DOI: 10.1111/ajt.14137] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
26 Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z; HCV-TARGET Study Group. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 2018;16:1811-1819.e4. [PMID: 29306043 DOI: 10.1016/j.cgh.2017.12.037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
27 Sebastiani G, Ghali P, Deschenes M, Wong P. Noninvasive diagnosis of liver fibrosis: The importance of being reimbursed. Can J Gastroenterol Hepatol 2015;29:219-20. [PMID: 25965444 DOI: 10.1155/2015/943410] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Francheville JW, Rankin R, Beck J, Hoare C, Materniak S, German G, Barrett L, Bunimov-Wall N, Smyth D. Early Successes in an Open Access, Provincially Funded Hepatitis C Treatment Program in Prince Edward Island. Ann Hepatol 2018;17:223-31. [PMID: 31097237 DOI: 10.5604/01.3001.0010.8637] [Reference Citation Analysis]
29 Wong WWL, Erman A, Feld JJ, Krahn M. Model-based projection of health and economic effects of screening for hepatitis C in Canada. CMAJ Open 2017;5:E662-72. [PMID: 28851700 DOI: 10.9778/cmajo.20170048] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
30 El-Shabrawi M, Hassanin F. Paediatric hepatitis C virus infection and its treatment: Present, past, and future. Arab J Gastroenterol 2019;20:163-74. [PMID: 31585703 DOI: 10.1016/j.ajg.2019.09.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Laupland KB, Valiquette L. The dollars and sense of chronic hepatitis C infection management. Can J Infect Dis Med Microbiol 2015;26:119-21. [PMID: 26236349 DOI: 10.1155/2015/301439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Fortier E, Høj SB, Sylvestre MP, Artenie AA, Minoyan N, Jutras-Aswad D, Grebely J, Bruneau J. Injecting frequency trajectories and hepatitis C virus acquisition: Findings from a cohort of people who inject drugs in Montréal, Canada. Int J Drug Policy 2021;96:103439. [PMID: 34518099 DOI: 10.1016/j.drugpo.2021.103439] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Tadrous M, Mason K, Dodd Z, Guyton M, Powis J, Mccormack D, Gomes T. Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada. CanLivJ 2021;4:51-8. [DOI: 10.3138/canlivj-2020-0025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Goodyear T, Brown H, Browne AJ, Hoong P, Ti L, Knight R. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments. Int J Equity Health 2021;20:81. [PMID: 33740984 DOI: 10.1186/s12939-021-01420-7] [Reference Citation Analysis]
35 Chan J, Young J, Cox J, Nitulescu R, Klein MB. Patterns of practice and barriers to care for hepatitis C in the direct-acting antiviral (DAA) era: A national survey of Canadian infectious diseases physicians. CanLivJ 2018;1:231-9. [DOI: 10.3138/canlivj.2018-0012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
36 Beyzaei H, Khosravi Z, Aryan R, Ghasemi B. A green one-pot synthesis of 3(5)-substituted 1,2,4-triazol-5(3)-amines as potential antimicrobial agents. J IRAN CHEM SOC 2019;16:2565-73. [DOI: 10.1007/s13738-019-01714-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
37 Darvishian M, Janjua NZ, Chong M, Cook D, Samji H, Butt ZA, Yu A, Alvarez M, Yoshida E, Ramji A, Wong J, Woods R, Tyndall M, Krajden M. Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk. J Viral Hepat 2018;25:1481-92. [PMID: 30047609 DOI: 10.1111/jvh.12977] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Wong WWL, Haines A, Bremner KE, Yao Z, Calzavara A, Mitsakakis N, Kwong JC, Sander B, Thein HH, Krahn MD. Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study. CMAJ Open 2021;9:E167-74. [PMID: 33688024 DOI: 10.9778/cmajo.20200162] [Reference Citation Analysis]
39 Belga S, Doucette KE. Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon. World J Gastroenterol 2016; 22(4): 1650-1663 [PMID: 26819530 DOI: 10.3748/wjg.v22.i4.1650] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
40 Al-Salama ZT, Deeks ED. Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4. Drugs. 2017;77:911-921. [PMID: 28417245 DOI: 10.1007/s40265-017-0739-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
41 Binitha RRV, Shajahan MA, Muhamed J, Anilkumar TV, Premlal S, Indulekha VC. Hepatoprotective effect of Lobelia alsinoides Lam. in Wistar rats. J Ayurveda Integr Med 2020;11:515-21. [PMID: 31277907 DOI: 10.1016/j.jaim.2019.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Alimohammadi A, Hakobyan S, Raycraft T, Vafadary S, Conway B. Evaluation of HCV treatment in people who actively inject drugs. Future Virology 2016;11:483-7. [DOI: 10.2217/fvl-2016-0042] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
43 Sicras-Mainar A, Navarro-Artieda R, Sáez-Zafra M. Comorbidity, concomitant medication, use of resources and healthcare costs associated with chronic hepatitis C virus carriers in Spain. Gastroenterol Hepatol 2018;41:234-44. [PMID: 29287992 DOI: 10.1016/j.gastrohep.2017.11.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
44 Sbarigia U, Denee TR, Turner NG, Wan GJ, Morrison A, Kaufman AS, Rice G, Dusheiko GM. Conceptual framework for outcomes research studies of hepatitis C: an analytical review. Infect Drug Resist 2016;9:101-17. [PMID: 27313473 DOI: 10.2147/IDR.S99329] [Reference Citation Analysis]
45 Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, Lim JK, Darling J, Pockros P, Galati JS, Frazier LM, Alqahtani S, Sulkowski MS, Vainorius M, Akushevich L, Fried MW, Zeuzem S; HCV-TARGET Study Group. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut 2017;66:1844-52. [PMID: 27418632 DOI: 10.1136/gutjnl-2016-311609] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 8.8] [Reference Citation Analysis]
46 Boucher LM, Bayoumi AM, Mark AE, Cooper C, Martin A, Marshall Z, Boyd R, Oickle P, Diliso N, Pineau D, Renaud B, LeBlanc S, Tyndall M, Lee OM, Kendall CE. Hepatitis C Testing, Status and Treatment among Marginalized People Who Use Drugs in an Inner City Setting: An Observational Cohort Study. Subst Use Misuse 2019;54:18-30. [PMID: 29932800 DOI: 10.1080/10826084.2018.1485699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
47 Tam E, Borgia S, Yoshida EM, Cooper C, Ford J, Vachon M, Sherman M, Halsey-brandt J. Real-world health care utilization in treatment of HCV: Results from the Canadian SIMPLE observational trial. CanLivJ 2019;2:91-107. [DOI: 10.3138/canlivj.2018-0024] [Reference Citation Analysis]
48 Lee AS, van Driel ML, Crawford DH. The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia. Clinicoecon Outcomes Res 2017;9:595-607. [PMID: 29042803 DOI: 10.2147/CEOR.S146280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
49 O'Neil CR, Pang JX, Lee SS, Swain MG, Burak KW, Klein P, Myers RP, Kapler J, Gill MJ, Labrie M, Coffin CS. Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients. Can J Infect Dis Med Microbiol 2015;26:293-6. [PMID: 26744584 DOI: 10.1155/2015/974871] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
50 Sarfaraz MO, Myers RP, Coffin CS, Gao ZH, Shaheen AA, Crotty PM, Zhang P, Vogel HJ, Weljie AM. A quantitative metabolomics profiling approach for the noninvasive assessment of liver histology in patients with chronic hepatitis C. Clin Transl Med. 2016;5:33. [PMID: 27539580 DOI: 10.1186/s40169-016-0109-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
51 Mahmud S, Biswas S, Paul GK, Mita MA, Promi MM, Afrose S, Hasan MR, Zaman S, Uddin MS, Dhama K, Emran TB, Saleh MA, Simal-Gandara J. Plant-Based Phytochemical Screening by Targeting Main Protease of SARS-CoV-2 to Design Effective Potent Inhibitors. Biology (Basel) 2021;10:589. [PMID: 34206970 DOI: 10.3390/biology10070589] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji A, Smyth D, Feld JJ; Canadian Association for the Study of the Liver. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ 2018;190:E677-87. [PMID: 29866893 DOI: 10.1503/cmaj.170453] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
53 Khan ST, Karges W, Cooper CL, Crawley AM. Hepatitis C virus core protein reduces CD8+ T-cell proliferation, perforin production and degranulation but increases STAT5 activation. Immunology 2018;154:156-65. [PMID: 29266204 DOI: 10.1111/imm.12882] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]